Basilea Pharmaceutica (XSWX:BSLN) Construction In Progress: CHF0.0 Mil (As of Dec. 2025)


XSWX:BSLN Basilea Pharmaceutica Ltd XSWX:BSLN
61 GF Score
Price CHF54.30
GF Value CHF57.52
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica Construction In Progress?

Basilea Pharmaceutica XSWX:BSLN +2.26% 61 Construction In Progress is CHF0.0 Mil as of Dec. 2025. GuruFocus rates XSWX:BSLN with a GF Score™ of 61/100 and a GF Value™ of CHF57.52 (Fairly Valued). The stock has 4 warning signs investors should review.

Basilea Pharmaceutica Construction In Progress Historical Data

* Premium members only.

The historical data trend for Basilea Pharmaceutica's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica Construction In Progress Chart

Basilea Pharmaceutica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Basilea Pharmaceutica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSWX:BSLN
61GF Score
Basilea Pharmaceutica Ltd XSWX:BSLN
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Basilea Pharmaceutica Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of CHF0.0 Mil mean?
Basilea Pharmaceutica (XSWX:BSLN) has a Construction In Progress of CHF0.0 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on Basilea Pharmaceutica and its competitors.
Is Basilea Pharmaceutica's Construction In Progress too high?
Basilea Pharmaceutica's current Construction In Progress is CHF0.0 Mil. Overall, Basilea Pharmaceutica has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Construction In Progress compare to VRTX and REGN?
Basilea Pharmaceutica's Construction In Progress of CHF0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current Construction In Progress is CHF0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Fairly Valued. The stock's GF Value™ is CHF57.52, compared to a current price of CHF54.30 — trading 5.6% below its estimated fair value. The current Construction In Progress is CHF0.0 Mil. Basilea Pharmaceutica's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Construction In Progress is CHF0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of CHF54.30 is trading 5.6% below its estimated GF Value™ of CHF57.52. GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.

Key valuation signals for XSWX:BSLN:

  • Construction In Progress: CHF0.0 Mil
  • GF Value™: CHF57.52 vs. price of CHF54.30 (5.6% below fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
61GF Score

Get the complete analysis for XSWX:BSLN

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF54.30
Price
CHF57.52
GF Value